Norwegian Cancer Society initiate investment fund

The newly employed Head of Biotech Investments in The Norwegian Cancer Society, Sigrid Fossheim, has already had several meetings with potential oncology companies to invest in. – We aim to make our first investment before the Summer of 2014, says Fossheim. The Norwegian Cancer Society is the largest private contributor to cancer research in Norway. […]

Excellent evaluation of Oslo Cancer Cluster

The six year evaluation of Oslo Cancer Cluster as a Norwegian Centre of Expertise concludes that Oslo Cancer Cluster is a strong biotech cluster, well positioned within the global oncology industry. “This plays well with our ambition to take the step up a level and become a Global Centre of Excellence,” says Jónas Einarsson, acting CEO […]

BerGen Bio develops novel treatment for leukemia

Oslo Cancer Cluster member BerGenBio announce that preclinical studies on the agent BGB324 may be effective as new treatment for patients with drug resistant Chronic Myeloid Leukemia (CML). The data was presented in a poster at the Annual Meeting of the American Society of Hematology (ASH) early December. It is estimated that CML accounts for […]

Helsemyggordning – financial instrument for health innovation

December 11th 2013, Oslo Cancer Cluster, Oslo Medtech and Nansen Neuroscience Network launched a proposal for a new financing mechanism to stimulate innovation from the health- and biotech industry. The proposal was very well received among the politicians, industry, public organisations and investors at the debate meeting in conjunction to the launch. Conservative Member of Parliament Kristin Vinje […]

Marketing authorisation for Bayer/Algeta`s prostate cancer treatment

Oslo Cancer Cluster member Bayer HealthCare announced Monday December 9th that they just received the marketing approval for Xofigo® (radium Ra 223 dichloride) by the Norwegian Medicines Agency. The approval came approximatelyone month after the European Commission granted marketing authorization in the EU for Xofigo® on November 15 2013. Xofigo has been developed by Oslo Cancer Cluster […]